ХРОНИЧЕСКАЯ СПОНТАННАЯ КРАПИВНИЦА: ВЫСОКИЕ ДОЗЫ И ДЛИТЕЛЬНОЕ ПРИМЕНЕНИЕ НЕСЕДАТИВНЫХ АНТИГИСТАМИННЫХ ПРЕПАРАТОВ ВТОРОГО ПОКОЛЕНИЯ. ОБЗОР ЛИТЕРАТУРЫ
Обзорная статья
Дата публикации: июля 13, 2022
Ключевые слова
хроническая крапивница
антигистаминные препараты 2 поколения
дезлоратадин
антигистаминные препараты 2 поколения
дезлоратадин
Как цитировать
[1]
.
Аннотация
Неседативные антигистаминные препараты второго поколения являются надежными препаратами первой и второй линии терапии при лечении больных с хронической крапивницей, как спонтанной, так и индуцированной, при этом в большинстве случаев необходимо длительное применение, а также использование увеличенных доз АГП. Для длительных курсов терапии увеличенными дозами антигистаминных препаратов следует отдавать предпочтение наиболее безопасным АГП. Рассмотрены вопросы эффективных доз, длительности курса, безопасности терапии, оценки эффективности и алгоритмов ведения пациентов.Литература
1. Клинические рекомендации по лечению больных крапивницей //М.: РОДВК. – 2020. [Clinical guidelines for the treatment of patients with urticaria. Moscow: RODVK. – 2020. In Russian].
2. Zuberbier T. et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria //Allergy. – 2022. – V. 77. – №. 3. – P. 734-766. doi: 10.1111/all.15090.
3. Круглова Л. С. Хроническая спонтанная крапивница: новости о проблеме и лечении (обзор литературы) //Медицинский алфавит. – 2019. – Т. 2. – №. 26. – С. 15-20. [Kruglova L.S. Chronic spontaneous urticaria: news about problem and treatment (literature review) //Medical alphabet. – 2019. – V. 2. – №. 26. – P. 15-20. In Russian]. doi: 10.33667/2078-5631-2019-2-26(401)-15-20.
4. Bracken S. J., Abraham S., MacLeod A. S. Autoimmune theories of chronic spontaneous urticaria //Frontiers in immunology. – 2019. – V. 10. – P. 627. doi: 10.3389/fimmu.2019.00627.
5. Kolkhir P. et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know //Journal of Allergy and Clinical Immunology. – 2017. – V. 139. – №. 6. – P. 1772-1781. doi: 10.1016/j.jaci.2016.08.050.
6. Church M. K. et al. The role and relevance of mast cells in urticaria //Immunological reviews. – 2018. – V. 282. – №. 1. – P. 232-247. doi: 10.1111/imr.12632.
7. Altrichter S. et al. IgE mediated autoallergy against thyroid peroxidase–a novel pathomechanism of chronic spontaneous urticaria? //PloS one. – 2011. – V. 6. – №. 4. – P. e14794. doi: 10.1371/journal.pone.0014794.
8. Schmetzer O. et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria //Journal of Allergy and Clinical Immunology. – 2018. – V. 142. – №. 3. – P. 876-882. doi: 10.1016/j.jaci.2017.10.035.
9. Hon K. L. et al. Chronic urticaria: an overview of treatment and recent patents //Recent Patents on Inflammation & Allergy Drug Discovery. – 2019. – V. 13. – №. 1. – P. 27-37. doi: 10.2174/1872213X13666190328164931.
10. Круглова Л.С., Татаурщикова Н.С., Типаева Е.В. Вопросы длительного применения антигистаминных препаратов //Фарматека. – 2021. – №14. – С.87-93. [Kruglova L.S., Tataurshchikova N.S., Tipaeva E.V. Issues of long-term use of antihistamines // Farmateka– 2021. – №14. – P. 87-93. In Russian].
11. Grattan C. E. H. et al. Plasmapheresis for severe, unremitting, chronic urticaria //The Lancet. – 1992. – V. 339. – №. 8801. – P. 1078-1080. doi:10.1016/0140- 6736(92)90666 – Q.
12. Kowalski M. L., Woessner K., Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug–related urticaria and angioedema //Journal of Allergy and Clinical Immunology. – 2015. – V. 136. – №. 2. – P. 245-251. doi: 10.1016/j.jaci.2015.06.021.
13. Zuberbier T. et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria //Dermatology. – 1996. – V. 193. – №. 4. – P. 324-327.
14. Cataldi M. et al. Cardiac safety of second‐generation H1‐antihistamines when updosed in chronic spontaneous urticaria //Clinical & Experimental Allergy. – 2019. – V. 49. – №. 12. – P. 1615-1623. doi: 10.1111/cea.13500.
15. Gillen M. S. et al. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval //British journal of clinical pharmacology. – 2001. – V. 52. – №. 2. – P. 201-204. doi: 10.1046/j.0306-5251.2001.01345.x.
16. DuBuske L. Desloratadine for chronic idiopathic urticaria //American journal of clinical dermatology. – 2007. – V. 8. – №. 5. – P. 271-283. doi: 10.2165/00128071-200708050-00002.
17. Choonhakarn C., Chaowattanapanit S., Julanon N. The treatment outcomes and dose de‐escalation of desloratadine up‐dosing in chronic spontaneous urticaria //International Journal of Dermatology. – 2018. – V. 57. – №. 4. – P. 423-427. doi: 10.1111/ijd.13919.
18. Grob J. J. et al. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life //Allergy. – 2009. – V. 64. – №. 4. – P. 605-612. doi: 10.1111/j.1398-9995.2008.01913.x.
19. Weller K. et al. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study //Acta dermato-venereologica. – 2013. – V. 93. – №. 2. – P. 168-174. doi: 10.2340/00015555-1434.
20. Siebenhaar F. et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study //Journal of Allergy and Clinical Immunology. – 2009. – V. 123. – №. 3. – P. 672-679. doi: 10.1016/j.jaci.2008.12.008.
21. Magerl M. et al. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H1‐antihistamine dose escalation //British Journal of Dermatology. – 2012. – V. 166. – №. 5. – P. 1095-1099. doi: 10.1111/j.1365-2133.2012.10822.x.
22. Гущин И.С., Антигистаминные препараты. М.: Aventis Pharma. – 2000. – С. 54. [Gushchin I.S., Antihistamines. Moscow: Aventis Pharma. – 2000. – P. 54. In Russian].
23. Карева Е.Н. Выбор антигистаминного препарата: взгляд фармаколога //РМЖ. – 2016. – №3. – С. 1-6. [Kareva E.N. The choice of an antihistamine drug: a pharmacologist's view // RMJ. – 2016. – №3. – P. 1-6. In Russian].
24. Sugiura K. et al. Evaluation of cetirizine hydrochloride-based therapeutic strategy for chronic urticaria //Nagoya J Med Sci. – 2008. – V. 70. – P. 97-106.
25. Kameyoshi Y. et al. Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients //British Journal of Dermatology. – 2007. – V. 157. – №. 4. – P. 803-804.
26. Okubo Y. et al. Double dose of cetirizine hydrochloride is effective for patients with urticaria resistant: a prospective, randomized, non-blinded, comparative clinical study and assessment of quality of life //Journal of dermatological treatment. – 2013. – V. 24. – №. 2. – P. 153-160. doi: 10.3109/09546634.2011.608783.
27. Zuberbier T. et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria //Dermatology. – 1996. – V. 193. – №. 4. – P. 324-327. doi: 10.1159/000246281.
28. Diepgen TL. Early Treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol. 2002 Aug;13(4):278-86.
29. Tanizaki H. et al. A double dose of levocetirizine leads to better control of histamine-induced flare, wheal and itch in healthy donors //Pharmacology. – 2013. – V. 92. – №. 1-2. – P. 71-74. doi: 10.1159/000353191.
30. Staevska M. et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria //Journal of Allergy and Clinical Immunology. – 2010. – V. 125. – №. 3. – P. 676-682.
31. Church D. S., Church M. K. Pharmacology of antihistamines. World Allergy Organ J 4 (Suppl 3): S22. – 2011.
32. Huang X., Li Z., Sun R. High-dose levocetirizine for the treatment of refractory chronic spontaneous urticaria and the effect on the serum inositol triphosphate level //Journal of International Medical Research. – 2019. – V. 47. – №. 9. – P. 4374-4379. doi: 10.1177/0300060519857768.
33. Sotes P. et al. Efficacy and safety of up-dosing antihistamines in chronic spontaneous urticaria: A systematic review of the literature //JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. – 2021. – V. 31. – №. 4. – P. 282-291. doi: 10.18176/jiaci.0649.
34. Godse K. Updosing of antihistamines to improve control of chronic urticaria //Indian Journal of Dermatology, Venereology, and Leprology. – 2010. – V. 76. – №. 1. – P. 61-61.
35. Sharma V. K. et al. An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose //Journal of Dermatological Treatment. – 2017. – V. 28. – №. 6. – P. 539-543. doi: 10.1080/09546634.2016.1246705.
36. Simons F. E. R., Early Prevention of Asthma in Atopic Children (EPAAC) Study Group*. Safety of levocetirizine treatment in young atopic children: An 18‐month study //Pediatric allergy and immunology. – 2007. – V. 18. – №. 6. – P. 535-542.
37. Sastre J. Ebastine in the treatment of allergic rhinitis and urticaria: 30 years of clinical studies and real-world experience //J Investig Allergol Clin Immunol. – 2020. – V. 30. – №. 3. – P. 156-168. doi: 10.18176/jiaci.0401.
38. Sastre J. Ebastine in allergic rhinitis and chronic idiopathic urticaria //Allergy. – 2008. – V. 63. – P. 1-20. doi: 10.1111/j.1398-9995.2008.01897.x.
39. Godse K. V. Ebastine in chronic spontaneous urticaria in higher doses //Indian Journal of Dermatology. – 2011. – V. 56. – №. 5. – P. 597. doi: 10.4103/0019-5154.87168.
40. Goyal V. et al. Comparative efficacy and safety of ebastine 20 mg, ebastine 10 mg and levocetirizine 5 mg in acute urticaria //Journal of Clinical and Diagnostic Research: JCDR. – 2017. – V. 11. – №. 3. – P. WC06. doi: 10.7860/JCDR/2017/23961.9550.
41. Rorer R. P. Open long-term study of the safety, tolerability of ebastine (LAS W 0-90) in patients with chronic urticaria (study CLIN 2.12) //Antony Cedex (France): Rhône-Poulenc Rorer. – 1988.
42. Rorer R. P. A long-term (one-year) safety and efficacy phase III study of ebastine (10mg) in the treatment of chronic urticaria in adult patients (study EBA 020) //Report no.: RP-64305-020. – V. 82.
43. Staevska M. T. Comparative efficacy of bilastine, levocetirizine and desloratadine updosing in chronic urticaria //Therapeutics and Clinical Risk Management. – 2016. – V. 12. – P. 1793. doi: 10.2147/TCRM.S120628.
2. Zuberbier T. et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria //Allergy. – 2022. – V. 77. – №. 3. – P. 734-766. doi: 10.1111/all.15090.
3. Круглова Л. С. Хроническая спонтанная крапивница: новости о проблеме и лечении (обзор литературы) //Медицинский алфавит. – 2019. – Т. 2. – №. 26. – С. 15-20. [Kruglova L.S. Chronic spontaneous urticaria: news about problem and treatment (literature review) //Medical alphabet. – 2019. – V. 2. – №. 26. – P. 15-20. In Russian]. doi: 10.33667/2078-5631-2019-2-26(401)-15-20.
4. Bracken S. J., Abraham S., MacLeod A. S. Autoimmune theories of chronic spontaneous urticaria //Frontiers in immunology. – 2019. – V. 10. – P. 627. doi: 10.3389/fimmu.2019.00627.
5. Kolkhir P. et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know //Journal of Allergy and Clinical Immunology. – 2017. – V. 139. – №. 6. – P. 1772-1781. doi: 10.1016/j.jaci.2016.08.050.
6. Church M. K. et al. The role and relevance of mast cells in urticaria //Immunological reviews. – 2018. – V. 282. – №. 1. – P. 232-247. doi: 10.1111/imr.12632.
7. Altrichter S. et al. IgE mediated autoallergy against thyroid peroxidase–a novel pathomechanism of chronic spontaneous urticaria? //PloS one. – 2011. – V. 6. – №. 4. – P. e14794. doi: 10.1371/journal.pone.0014794.
8. Schmetzer O. et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria //Journal of Allergy and Clinical Immunology. – 2018. – V. 142. – №. 3. – P. 876-882. doi: 10.1016/j.jaci.2017.10.035.
9. Hon K. L. et al. Chronic urticaria: an overview of treatment and recent patents //Recent Patents on Inflammation & Allergy Drug Discovery. – 2019. – V. 13. – №. 1. – P. 27-37. doi: 10.2174/1872213X13666190328164931.
10. Круглова Л.С., Татаурщикова Н.С., Типаева Е.В. Вопросы длительного применения антигистаминных препаратов //Фарматека. – 2021. – №14. – С.87-93. [Kruglova L.S., Tataurshchikova N.S., Tipaeva E.V. Issues of long-term use of antihistamines // Farmateka– 2021. – №14. – P. 87-93. In Russian].
11. Grattan C. E. H. et al. Plasmapheresis for severe, unremitting, chronic urticaria //The Lancet. – 1992. – V. 339. – №. 8801. – P. 1078-1080. doi:10.1016/0140- 6736(92)90666 – Q.
12. Kowalski M. L., Woessner K., Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug–related urticaria and angioedema //Journal of Allergy and Clinical Immunology. – 2015. – V. 136. – №. 2. – P. 245-251. doi: 10.1016/j.jaci.2015.06.021.
13. Zuberbier T. et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria //Dermatology. – 1996. – V. 193. – №. 4. – P. 324-327.
14. Cataldi M. et al. Cardiac safety of second‐generation H1‐antihistamines when updosed in chronic spontaneous urticaria //Clinical & Experimental Allergy. – 2019. – V. 49. – №. 12. – P. 1615-1623. doi: 10.1111/cea.13500.
15. Gillen M. S. et al. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval //British journal of clinical pharmacology. – 2001. – V. 52. – №. 2. – P. 201-204. doi: 10.1046/j.0306-5251.2001.01345.x.
16. DuBuske L. Desloratadine for chronic idiopathic urticaria //American journal of clinical dermatology. – 2007. – V. 8. – №. 5. – P. 271-283. doi: 10.2165/00128071-200708050-00002.
17. Choonhakarn C., Chaowattanapanit S., Julanon N. The treatment outcomes and dose de‐escalation of desloratadine up‐dosing in chronic spontaneous urticaria //International Journal of Dermatology. – 2018. – V. 57. – №. 4. – P. 423-427. doi: 10.1111/ijd.13919.
18. Grob J. J. et al. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life //Allergy. – 2009. – V. 64. – №. 4. – P. 605-612. doi: 10.1111/j.1398-9995.2008.01913.x.
19. Weller K. et al. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study //Acta dermato-venereologica. – 2013. – V. 93. – №. 2. – P. 168-174. doi: 10.2340/00015555-1434.
20. Siebenhaar F. et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study //Journal of Allergy and Clinical Immunology. – 2009. – V. 123. – №. 3. – P. 672-679. doi: 10.1016/j.jaci.2008.12.008.
21. Magerl M. et al. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H1‐antihistamine dose escalation //British Journal of Dermatology. – 2012. – V. 166. – №. 5. – P. 1095-1099. doi: 10.1111/j.1365-2133.2012.10822.x.
22. Гущин И.С., Антигистаминные препараты. М.: Aventis Pharma. – 2000. – С. 54. [Gushchin I.S., Antihistamines. Moscow: Aventis Pharma. – 2000. – P. 54. In Russian].
23. Карева Е.Н. Выбор антигистаминного препарата: взгляд фармаколога //РМЖ. – 2016. – №3. – С. 1-6. [Kareva E.N. The choice of an antihistamine drug: a pharmacologist's view // RMJ. – 2016. – №3. – P. 1-6. In Russian].
24. Sugiura K. et al. Evaluation of cetirizine hydrochloride-based therapeutic strategy for chronic urticaria //Nagoya J Med Sci. – 2008. – V. 70. – P. 97-106.
25. Kameyoshi Y. et al. Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients //British Journal of Dermatology. – 2007. – V. 157. – №. 4. – P. 803-804.
26. Okubo Y. et al. Double dose of cetirizine hydrochloride is effective for patients with urticaria resistant: a prospective, randomized, non-blinded, comparative clinical study and assessment of quality of life //Journal of dermatological treatment. – 2013. – V. 24. – №. 2. – P. 153-160. doi: 10.3109/09546634.2011.608783.
27. Zuberbier T. et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria //Dermatology. – 1996. – V. 193. – №. 4. – P. 324-327. doi: 10.1159/000246281.
28. Diepgen TL. Early Treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol. 2002 Aug;13(4):278-86.
29. Tanizaki H. et al. A double dose of levocetirizine leads to better control of histamine-induced flare, wheal and itch in healthy donors //Pharmacology. – 2013. – V. 92. – №. 1-2. – P. 71-74. doi: 10.1159/000353191.
30. Staevska M. et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria //Journal of Allergy and Clinical Immunology. – 2010. – V. 125. – №. 3. – P. 676-682.
31. Church D. S., Church M. K. Pharmacology of antihistamines. World Allergy Organ J 4 (Suppl 3): S22. – 2011.
32. Huang X., Li Z., Sun R. High-dose levocetirizine for the treatment of refractory chronic spontaneous urticaria and the effect on the serum inositol triphosphate level //Journal of International Medical Research. – 2019. – V. 47. – №. 9. – P. 4374-4379. doi: 10.1177/0300060519857768.
33. Sotes P. et al. Efficacy and safety of up-dosing antihistamines in chronic spontaneous urticaria: A systematic review of the literature //JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. – 2021. – V. 31. – №. 4. – P. 282-291. doi: 10.18176/jiaci.0649.
34. Godse K. Updosing of antihistamines to improve control of chronic urticaria //Indian Journal of Dermatology, Venereology, and Leprology. – 2010. – V. 76. – №. 1. – P. 61-61.
35. Sharma V. K. et al. An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose //Journal of Dermatological Treatment. – 2017. – V. 28. – №. 6. – P. 539-543. doi: 10.1080/09546634.2016.1246705.
36. Simons F. E. R., Early Prevention of Asthma in Atopic Children (EPAAC) Study Group*. Safety of levocetirizine treatment in young atopic children: An 18‐month study //Pediatric allergy and immunology. – 2007. – V. 18. – №. 6. – P. 535-542.
37. Sastre J. Ebastine in the treatment of allergic rhinitis and urticaria: 30 years of clinical studies and real-world experience //J Investig Allergol Clin Immunol. – 2020. – V. 30. – №. 3. – P. 156-168. doi: 10.18176/jiaci.0401.
38. Sastre J. Ebastine in allergic rhinitis and chronic idiopathic urticaria //Allergy. – 2008. – V. 63. – P. 1-20. doi: 10.1111/j.1398-9995.2008.01897.x.
39. Godse K. V. Ebastine in chronic spontaneous urticaria in higher doses //Indian Journal of Dermatology. – 2011. – V. 56. – №. 5. – P. 597. doi: 10.4103/0019-5154.87168.
40. Goyal V. et al. Comparative efficacy and safety of ebastine 20 mg, ebastine 10 mg and levocetirizine 5 mg in acute urticaria //Journal of Clinical and Diagnostic Research: JCDR. – 2017. – V. 11. – №. 3. – P. WC06. doi: 10.7860/JCDR/2017/23961.9550.
41. Rorer R. P. Open long-term study of the safety, tolerability of ebastine (LAS W 0-90) in patients with chronic urticaria (study CLIN 2.12) //Antony Cedex (France): Rhône-Poulenc Rorer. – 1988.
42. Rorer R. P. A long-term (one-year) safety and efficacy phase III study of ebastine (10mg) in the treatment of chronic urticaria in adult patients (study EBA 020) //Report no.: RP-64305-020. – V. 82.
43. Staevska M. T. Comparative efficacy of bilastine, levocetirizine and desloratadine updosing in chronic urticaria //Therapeutics and Clinical Risk Management. – 2016. – V. 12. – P. 1793. doi: 10.2147/TCRM.S120628.